![(R)-Nepicastat HCl [RS-25560-198 HCl]](/upload/0201/CgAGS12aCm6AB2_7AABKJJYDSXY189.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
(R)-Nepicastat HCl (R-SYN117; R-SYN-117; R-RS-25560-198 HCl), the R-enantiomer of Nepicastat HCl (RS-25560-197; SYN117; SYN-117; RS25560197), is a selective inhibitor with IC50 of 25.1 nM and 18.3 nM for bovine and human dopamine-β-hydroxylases (enzymes catalyzing the transformation of dopamine to norepinephrine) with the potential to treat congestive heart failure.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Br J Pharmacol.1997 Aug;121(8):1803-9.
|
| Molecular Formula |
C14H15F2N3S.HCL
|
|
|---|---|---|
| Molecular Weight |
331.81
|
|
| Exact Mass |
331.072
|
|
| CAS # |
195881-94-8
|
|
| Related CAS # |
|
|
| PubChem CID |
54536287
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| LogP |
4.514
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
4
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
20
|
|
| Complexity |
429
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
Cl.NCC1=CNC(=S)N1[C@@H]1CCC2=C(C=C(C=C2C1)F)F
|
|
| InChi Key |
YZZVIKDAOTXDEB-SNVBAGLBSA-N
|
|
| InChi Code |
InChI=1S/C14H15F2N3S/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20/h3,5,7,10H,1-2,4,6,17H2,(H,18,20)/t10-/m1/s1
|
|
| Chemical Name |
4-(aminomethyl)-3-[(2R)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1H-imidazole-2-thione
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0138 mL | 15.0689 mL | 30.1377 mL | |
| 5 mM | 0.6028 mL | 3.0138 mL | 6.0275 mL | |
| 10 mM | 0.3014 mL | 1.5069 mL | 3.0138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Figure 2Effects of nepicastat on tissue noradrenaline (NA) and dopamine (DA) content in the mesenteric artery (a), left ventricle (b) and cerebral cortex (c) of SHRs.Br J Pharmacol.1997 Aug;121(8):1803-9. |
|---|
 |
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
Effects of nepicastat on tissue dopamine/noradrenaline ratio in the mesenteric artery, left ventricle and cerebral cortex of SHRs.